AAV Targeting Kidney: Serotypes, Promoters & Dosage Guide

[On-Target] AAV Targeting the Kidney — Serotypes, Promoters & Dosages: All You Need in One Guide!

2026-07-20

The kidney is a vital organ for physiological metabolism. In mammals, the bean-shaped kidney is primarily divided into two regions: the outer renal cortex, where initial urine formation occurs, and the underlying renal medulla, which consists of renal pyramids responsible for further urine concentration. The functional unit of the kidney is the nephron, which is composed of the renal corpuscle and the renal tubule.

In addition to excreting waste by filtering metabolic byproducts from the blood into urine, the kidneys regulate water and electrolyte balance while maintaining acid-base homeostasis. Furthermore, the kidney functions as an endocrine organ, producing erythropoietin (EPO) to promote red blood cell production, and releasing renin to regulate blood pressure. It also plays a metabolic role by synthesizing active vitamin D to regulate calcium and phosphorus metabolism. Ultimately, the kidneys play a key role in maintaining systemic homeostasis.

The structure of the kidney

(Blausen.com staff, WikiJournal of Medicine, 2014)

Nephron: The basic functional unit of the kidney

(Picture from NIDDK, NIH)

Kidney diseases are reported to affect up to 13% of the global population, with chronic kidney disease (CKD) recognized as a major global health burden. CKD is a long-term condition characterized by a gradual loss of renal function or structural abnormalities persisting for more than three months. Late-stage CKD can progress to kidney failure, renal fibrosis, and uremia. Common etiologies include chronic nephritis, hypertension, and diabetes.

Diabetic kidney disease (DKD)—CKD caused by diabetes—results from chronic poor glycemic control, which damages the glomeruli and renal tubules, leading to a progressive decline in kidney function. Beyond CKD and DKD, other major areas of current kidney research include polycystic kidney disease (PKD) and acute kidney injury (AKI), including renal ischemia-reperfusion injury (IRI).

Given the complex structure and function of the kidney, investigations into its pathological mechanisms and therapeutic strategies are frequently coupled with gene delivery and gene therapy. Recombinant adeno-associated virus (rAAV) vectors have become the dominant tool for gene functional studies and gene therapy delivery due to their diverse serotypes, low immunogenicity, long-term stable transgene expression, and broad host range. Consequently, an increasing number of researchers are utilizing AAV vectors to efficiently transduce the kidney.

01. Selecting the Right AAV Serotype

Choosing the optimal AAV serotype depends heavily on the target tissue. Serotypes such as AAV9, AAV8, AAV6, and AAV2 have been successfully used to target the kidney. Among these, AAV9 is the most widely adopted serotype in renal research and is compatible with various administration routes.

AAV9 targeting the kidney

(C J Rocca, et al., Gene Therapy, 2014)

02. Selecting the Right Promoter

Because different regions of the kidney serve distinct functions, the cell types within them are highly diverse. Renal podocytes—the visceral epithelial cells of Bowman’s capsule—are essential components of the glomerular filtration barrier. Podocyte-specific targeting can be achieved using the NPHS1 or NPHS2 promoter.

Renal tubular epithelial cells, which are responsible for urine formation and regulation, can be targeted using the Kspc promoter. Based on their structural and functional characteristics, these tubular epithelial cells can be further subdivided:

Proximal tubule cells can be specifically targeted using the SGLT2 promoter.
Cells of the thick ascending limb (TAL) of the loop of Henle can be targeted using the NKCC2 promoter.
Renal collecting duct cells can be specifically transduced using the ECAD promoter.

Kidney-specific promoter

(Laureano D Asico, et al., Biochem Biophys Res Commun., 2018)

03. Routes of Administration and Dosages

While tail vein injection is the most common systemic route for AAV delivery and is highly applicable to kidney-targeted gene therapy, several kidney-specific localized injection routes are also widely used. These include renal pelvis injection, retrograde ureteral injection, and renal parenchyma injection.

Route of Administration	Recommended Dosage	Injection Volume
Tail Vein Injection	~5E+11 vg/mouse	100–200 μL
Renal Pelvis Injection	~2E+11 vg/side	~50 μL
Retrograde Ureteral Injection	~1E+11 vg/mouse	50–100 μL
Renal Parenchyma Injection	~1E+11 vg/side	~50 μL

04. Client Case Studies

Case 1: Renal Fibrosis Research

Renal fibrosis is a hallmark pathological change that drives the progression of chronic kidney disease. A research team identified the E3 ubiquitin ligase TRIM65 as a positive regulator of renal fibrosis. TRIM65 promotes renal fibrosis by modulating NUDT21-mediated alternative polyadenylation (APA).

To investigate this mechanism in vivo, the researchers used AAV9 via renal pelvis injection to knock down NUDT21 expression in mice. They observed that NUDT21 knockdown aggravated unilateral ureteral obstruction (UUO)-induced renal fibrosis in wild-type mice and blocked the protective effects typically offered by TRIM65 deficiency.

(Liguo Zhu, et al., Advanced Science, 2023)

Viral vector	AAV9-si-NUDT21, AAV9-si-Control
Injected animal	Mouse
Injection method	Renal pelvis injection
Injection dose	2E+11vg, 50μL
Infected site	Kidney
Detection time	3w

Case 2: Tubular Atrophy Research

Tubular atrophy is another prominent manifestation of chronic kidney disease. A study demonstrated that a decline in PNPT1 within renal tubular cells triggers translational arrest and subsequent tubular atrophy. Conversely, restoring renal PNPT1 expression or suppressing PKR activity significantly alleviated tubular injury in mice with renal dysfunction.

To validate this in vivo, the researchers utilized an AAV vector to overexpress PNPT1 in the kidneys of an ischemia-reperfusion injury (IRI) mouse model. This local intervention led to a marked reduction in tubular cell apoptosis in the IRI mice.

(Yujie Zhu, et al., Nature Communications, 2023)

Viral vector	AAV-PNPT1, AAV-Ctrl
Injected animal	Mouse
Injection method	In situ injection
Injection dose	1E+13vg/mL, 20μL
Infected site	Kidney
Detection time	3w

Case 3: Proteinuric Kidney Disease & DKD

Diseases characterized by excessive protein excretion in the urine are collectively termed proteinuric kidney diseases, which include DKD. Emerging evidence suggests that abnormal lipid accumulation in podocytes is a critical pathological driver of proteinuric kidney diseases.

A research team discovered that podocyte-specific Dock5 deficiency exacerbates podocyte injury and glomerular pathology in proteinuric nephropathy. This process is mediated by the regulation of the LXRα/CD36 signaling pathway, which governs fatty acid uptake.

To determine whether LXRα is the key downstream effector of Dock5 in podocytes, the researchers performed podocyte-specific LXRα knockdown in Dock5 conditional knockout (cKO) diabetic mice. By delivering AAV2-Nphs1-shLXRα, they successfully knocked down LXRα specifically in podocytes, which significantly rescued the pathological phenotype and attenuated the defects induced by Dock5 deficiency.